Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19
Open Access
- 23 December 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 7, 614393
- https://doi.org/10.3389/fmed.2020.614393
Abstract
Famotidine is of interest as a possible treatment for COVID-19, with effects on disease-related symptoms and survival reported in observational and retrospective studies, as well as in silico predictions of binding to potential SARS-CoV-2 drug targets. Published studies of famotidine for COVID-19 have focused on acute illness, and none have reported on neuropsychiatric symptoms. This case study reports on an 18-year-old man who sought psychiatric treatment for depression and anxiety, disruptive interpersonal conflicts, and impairments in attention and motivation following mildly symptomatic illness with COVID-19. The neuropsychiatric symptoms, which had been present for 16 weeks at the time of the initial evaluation represented a significant departure from the patient's previous behavioral baseline. The patient had no prior psychiatric history preceding his illness with COVID-19, and no history of any prior treatment with psychopharmacological medications. Famotidine 20 mg twice daily administered orally was begun without any additional medications. At 1-week follow-up the patient was much improved. Improvement was sustained through 12 weeks of follow-up during which the patient continued to take famotidine without apparent side effects. With progression of the COVID-19 pandemic it has become evident that persistent disease-related symptoms may follow acute COVID-19 and may include neuropsychiatric symptoms. Controlled clinical research on famotidine for COVID-19 should follow, as well as the development of valid and reliable research diagnostic criteria to define and operationalize the features of a putative COVID-19 neuropsychiatric residual.This publication has 28 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and OutcomesThe American Journal of Gastroenterology, 2020
- Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19Gastroenterology, 2020
- Medication for COVID-19—an Overview of Approaches Currently Under StudyDeutsches Ärzteblatt international, 2020
- Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronavirusesBiochemical and Biophysical Research Communications, 2020
- Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patientsChinese Medical Journal, 2020
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methodsActa Pharmaceutica Sinica. B, 2020
- Neuroinflammation and psychiatric illnessJournal of Neuroinflammation, 2013
- Reliability and validity of the beck anxiety inventoryJournal of Anxiety Disorders, 1992
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961